High
FDA
FDA reclassifies ISH test systems for oncology therapeutics from Class III to Class II
The change lowers regulatory burden for companion diagnostic ISH tests while maintaining safety and effectiveness through special controls. The FDA has issued a final order reclassifying in situ hybridization (ISH) test systems indicated for use with a corresponding approved oncology therapeutic...
Create a free account to read this complete brief and one more from every weekly edition. No card required.
Create a free accountSources — verify every claim